omniture
logo
Search
Sirnaomic
Media Room

Latest News

rss

Sirnaomics Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer In Situ

Data results will be available in Q1 2023 GAITHERSBURG, Md. and SUZHOU, China, Aug. 19, 2022 /PRNew...

2022-08-19 13:31 2288

Sirnaomics Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer In Situ

Data results will be available in Q1 2023 GAITHERSBURG, Md. and SUZHOU, China, Aug. 18, 2022 /PRNew...

2022-08-18 23:46 1427

Sirnaomics Develops Peptide Docking Vehicle (PDoV(TM)) Designed for an Enhanced GalNAc Delivery Platform for Novel siRNA Therapeutics

A proprietary GalNAc delivery system with enhanced Endosome Escape and Dual-Targeting GAITHERSBURG...

2022-08-16 14:48 3021

Sirnaomics Receives IND Clearance from the "Taiwan Ministry of Health and Welfare" for Phase I Clinical Study of RNAi Therapeutic STP705 for Liver Cancer Treatment

GAITHERSBURG, Md. and SUZHOU, China, July 26, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" o...

2022-07-26 16:58 2455

Sirnaomics to Present the Latest Developments of Dual-Targeted RNAi Therapeutics based on its Proprietary GalAhead™ Program at the 4th Annual RNA Therapeutic: From Concept to Clinic Symposium

GAITHERSBURG, Md. and SUZHOU, China, June 22, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" o...

2022-06-22 00:29 2825

Sirnaomics Announces Publication of STP705 Clinical Study Results for Treatment of isSCC in the Peer-Reviewed Journal of Drugs in Dermatology

GAITHERSBURG, Md. and SUZHOU, China, June 16, 2022 /PRNewswire/ -- Sirnaomics Ltd. ("Sirnaomics", s...

2022-06-16 13:01 2484

Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Cosmetology Treatment

GAITHERSBURG, Md. and SUZHOU, China, May 30, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or...

2022-05-30 16:40 2378

Sirnaomics will present clinical study results and development strategy for Cancer RNA Therapeutics at the 2022 Pre-ASCO China Summit

GAITHERSBURG, Md. and SUZHOU, China, May 20, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or...

2022-05-20 12:31 3166

Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and GalAhead™ Programs at the TIDES USA 2022

GAITHERSBURG, Md. and SUZHOU, China, May 11, 2022 /PRNewswire/ -- Sirnaomics Ltd.

2022-05-11 13:05 2477

Sirnaomics Doses First Subject in Phase I Clinical Trial of STP707 for the Treatment of Liver Fibrosis in Primary Sclerosing Cholangitis

HONG KONG, April 4, 2022 /PRNewswire/ -- Sirnaomics Ltd. ("Sirnaomics,...

2022-04-04 21:31 3032

RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines

GAITHERSBURG, Md., March 30, 2022 /PRNewswire/ -- RNAimmune, Inc. (the "Company " or "RNAimmune"), a...

2022-03-30 08:31 2164

Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide & Precision Therapeutics Congress

Sirnaomics CTO Dmitry Samarsky, PhD, to Also Present OPT Congress Opening Remarks HONG KONG, March...

2022-03-15 12:47 2249

Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide & Precision Therapeutics Congress

Sirnaomics CTO Dmitry Samarsky, PhD, to Also Present OPT Congress Opening Remarks GAITHERSBURG, Md...

2022-03-15 00:06 1923
123